TL;DR: Skip the subscription stress and get Microsoft Office Professional 2021 with all your favorite productivity tools for $59.97. Word, Excel, PowerPoint, Outlook, Publisher, and Access all in one ...

Now may be the best time to opt for Microsoft Office since it's price has been cut to $34.97 (reg. $229). You'll just have to ...

Instead of paying $9.99 monthly, just get an Office lifetime license for $59.97 while they’re 72% off. If you cancel your ...

The forecast for 2025 is broadly unchanged from that in the October 2024 World Economic Outlook (WEO), primarily on account of an upward revision in the United States offsetting downward revisions in ...

Why it matters: The increase in game license issuance bodes well for the outlook of gaming companies in China. More importantly, it indicates that regulators are adopting a more supportive stance ...

Purchase Current Issue or Download the PDF of this Issue Remembering Carter as we steel ourselves for Trump’s second inauguration. D.D. Guttenplan Though he started by threatening Mexico ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Software companies’ performance can be a bit volatile on an annualized basis and thus it is better to value them on DCF basis to capture their true potential in the nearto-medium term.

Capital One users were reporting issues with receiving their deposits on Thursday morning, leaving many customers wondering where their money and paychecks are. Complaints on social media were ...

7-nm and more advanced technologies comprised 74% of the total wafer revenue. Outlook: Taiwan Semiconductor is guided for first-quarter 2025 revenue of $25.0 billion-$25.8 billion versus the $24. ...

We explore some of the key trends in the UK shaping the legal outlook for the tech sector. Signs of recovery in tech M&A and investment With growth in the value of global tech M&A and investment in ...

Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.